Neuromyelitis optica

Current Treatment Options in Neurology

Volumn 10, Issue 1, 2008, Pages 55-66

  Wingerchuk, Dean M ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMFEBUTAMONE; ANALGESIC AGENT; ANTACID AGENT; ANTICONVULSIVE AGENT; AQUAPORIN 4; AUTOANTIBODY; AZATHIOPRINE; BOTULINUM TOXIN; COLESTYRAMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHINYLESTRADIOL; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LIVE VACCINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACNE; ACUTE KIDNEY FAILURE; ADRENAL CORTEX INSUFFICIENCY; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANXIETY; APLASTIC ANEMIA; ASEPTIC MENINGITIS; ASTHENIA; AUTOIMMUNITY; AVASCULAR NECROSIS; BACKACHE; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS; BRONCHOSPASM; CARDIOTOXICITY; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CUSHING SYNDROME; DEMYELINATING NEUROPATHY; DEPRESSION; DERMATITIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EUPHORIA; FERTILITY; FLUID RETENTION; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INFECTION; INFERTILITY; INFLAMMATION; KINESIOTHERAPY; LEUKEMIA; LEUKOPENIA; LICHENOID ERUPTION; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MEGALOBLASTIC ANEMIA; MENSTRUATION DISORDER; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MYALGIA; MYELITIS; MYELODYSPLASIA; MYELOOPTIC NEUROPATHY; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PEMPHIGUS; PEPTIC ULCER; PERIPHERAL EDEMA; PHYSIOTHERAPY; PLASMAPHERESIS; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RECURRENT DISEASE; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; SKIN ATROPHY; SODIUM RETENTION; SPASTICITY; SPINAL CORD LESION; STEVENS JOHNSON SYNDROME; TASTE AVERSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREMOR; TUBERCULOSIS; URINARY TRACT INFECTION; URTICARIA; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 38749151836     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0007-z     Document Type: Review

References (46)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al.: The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:810-815.
2. Wingerchuk DM, Weinshenker BG: Neuromyelitis optica. Curr Treat Options Neurol 2005, 7:173-182.
3. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
4. Saiz A, Zuliani L, Blanco Y, et al., for the Spanish-Italian NMO Study Group: Revised diagnostic criteria for neuromyelitis optica (NMO): application in a series of suspected patients. J Neurol 2007 [Epub ahead of print].
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
7. Jarius S, Franciotta D, Bergamaschi R, et al.: NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
8. Matsuoka T, Matsushita T, Kawano Y, et al.: Heterogeneity of aquaporin 4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130:1206-1223.
9. Takahashi T, Fujihara K, Nakashima I, et al.: Anti-aquaporin 4 antibody is involved in the pathogenesis of NMO: a study on antibody titer. Brain 2007, 130:1235-1243.
10. Pittock SJ, Lennon VA, Krecke K, et al.: Brain MRI abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390-396.
11. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964-968.
12. Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
13. Sinclair C, Kirk J, Herron B, et al.: Absence of aquaporin 4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal appearing white matter. Acta Neuropathol 2007, 113:187-194.
14. Roemer SF, Parisi JE, Lennon VA, et al.: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
15. Misu T, Fujihara K, Kakita A, et al.: Loss of aquaporin-4 in lesions in neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224-1234.
16. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenken BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
17. Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
18. Wingerchuk DM, Weinshenker BG: Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003, 60:848-853.
19. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603-605.
20. Filippini C, Brusaferri F, Sibley WA, et al.: Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000, CD001331.
21. Beck RW, Cleary PA, Anderson MM Jr, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581-588.
22. The Optic Neuritis Study Group: Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997, 115:1545-1552.
23. Brusaferri F, Candelise L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000, 247:435-442.
24. Yan J, Richert JR, Sirdofsky MD: High-dose intravenous immunoglobulin for multiple sclerosis. Lancet 1990, 336:692.
25. Visser LH, Beckman R. Tijssen CC, et al.: A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004, 10:89-91.
26. Sorensen PS, Haas J, Sellebjerg F, et al.; TARIMS Study Group: IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004, 63:2028-2033.
27. Nos C, Comabella M, Tintore M, et al.: High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 61:418-419.
28. Chrousos GA, Kattah JC, Beck RW, et al.: Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 1993, 269:2110-2112.
29. Saida T, Tashiro K, Itoyama Y, et al.: Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005, 64:621-630.
30. Papeix C, Vidal JS, de Seze J, et al.: Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:256-259.
31. Warabi Y, Matsumoto Y, Hayashi H: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:257-261.
32. Mandler RN, Ahmed W, Dencoff JE: Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219-1220.
33. Watanabe S, Misu T, Miyazawa I, et al.: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007, 13:968-974.
34. Remuzzi G, Lesti M, Gotti E, et al.: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503-512.
35. Cree BA, Lamb S, Morgan K, et al.: An open-label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
36. Jacob A, Weinshenker B, McLinskey N, et al.: Retrospective analysis of rituximab treatment of 24 cases of neuromyelitis optica [abstract]. Neurology 2007, 68(Suppl 1):A206.
37. Rituxan warning. FDA Consum 2007, 41(2):3.
38. Bakker J, Metz L: Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265-267.
39. Hartung HP, Gonsette R, Konig N, et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002, 360:2018-2025.
40. Goodin DS, Arnason BG, Coyle PK, et al.: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:1332-1338.
41. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al.: Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006, 63:957-963.
42. Minagar A, Sheremata WA: Treatment of Devic's disease with methotrexate and prednisone. Intl J MS Care (Serial online) 2000, 2(4). Available at http://www.mscare.org/cmsc/images/pdf/ ijmsc-2000-dec.pdf. Accessed Oct. 16, 2007.
43. Weinshenker BG, O'Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
44. Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of demyelination: predictors of response. Neurology 2001, 58:143-146.
45. Watanabe S, Nakashima I, Misu T, et al.: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007, 13:128-132.
46. Ruprecht K, Klinker E, Dintelmann T, et al.: Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004, 63:1081-1083.